Brief: Precision Biosciences Receives FDA Orphan Drug Designation For Pbgene-Dmd For The Treatment Of Duchenne Muscular Dystrophy
23/07/2025 12:01
July 23 (Reuters) - Precision BioSciences Inc DTIL.O: PRECISION BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR PBGENE-DMD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY PRECISION BIOSCIENCES INC - CLINICAL DATA FOR PBGENE-DMD EXPECTED IN 2026 Source text: ID:nBw9GS74La Further company coverage: DTIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing